Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration
暂无分享,去创建一个
Kasper Bendix Johnsen | H. H. Andersen | Torben Moos | T. Moos | K. B. Johnsen | Hjalte Holm Andersen | H. Andersen
[1] Katsuhide Ito,et al. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases , 1995, Journal of the Neurological Sciences.
[2] Y. Imai,et al. Extracellular ATP or ADP Induce Chemotaxis of Cultured Microglia through Gi/o-Coupled P2Y Receptors , 2001, The Journal of Neuroscience.
[3] H J Koch,et al. A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.
[4] J. Bijlsma,et al. Synovium in haemophilic arthropathy , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] A. McKinney,et al. Proton MR spectroscopy in Wilson disease: analysis of 36 cases. , 2005, AJNR. American journal of neuroradiology.
[6] E. Morgan,et al. Transferrin and Iron Uptake by the Brain: Effects of Altered Iron Status , 1991, Journal of neurochemistry.
[7] B. Gwag,et al. Iron mediates endothelial cell damage and blood-brain barrier opening in the hippocampus after transient forebrain ischemia in rats , 2011, Experimental & Molecular Medicine.
[8] C. Marsden,et al. INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.
[9] J. Connor,et al. Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains , 1997, Neuroscience.
[10] R. Ferrante,et al. Huntington's disease: progress and potential in the field , 2007, Expert opinion on investigational drugs.
[11] M. Bradbury. Transport of Iron in the Blood‐Brain‐Cerebrospinal Fluid System , 1997, Journal of neurochemistry.
[12] J. Andersen,et al. Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? , 2010, Journal of neurochemistry.
[13] Wei Zhang,et al. Intracellular metal ion chelators inhibit TNFalpha-induced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. , 2003, Free radical biology & medicine.
[14] Yinghe Hu,et al. Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration , 2012, Translational Neurodegeneration.
[15] G. Gerhard,et al. Perspective: Atherosclerosis: a manifestation of chronic iron toxicity? , 2003 .
[16] J. Growdon,et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. , 2011, The American journal of pathology.
[17] A. Tolkovsky,et al. Inhibition of Microglial Phagocytosis Is Sufficient To Prevent Inflammatory Neuronal Death , 2011, The Journal of Immunology.
[18] J. Connor,et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.
[19] J. Araujo,et al. Iron overload augments the development of atherosclerotic lesions in rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[20] H. Schumacher. Arthropathy in hemochromatosis. , 1998, Hospital practice.
[21] J. Ryu,et al. A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.
[22] A. Suzumura. Neuron-microglia interaction in neuroinflammation. , 2013, Current protein & peptide science.
[23] J. Zimmer,et al. Population control of resident and immigrant microglia by mitosis and apoptosis. , 2007, The American journal of pathology.
[24] D. Mann,et al. Pathological relationships between microglial cell activity and tau and amyloid β protein in patients with Alzheimer's disease , 2002, Neuroscience Letters.
[25] G. Bing,et al. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.
[26] Z. Qian,et al. Role of hepcidin in murine brain iron metabolism , 2009, Cellular and Molecular Life Sciences.
[27] F. Visseren,et al. Intracellular labile iron promotes firm adhesion of human monocytes to endothelium under flow and transendothelial migration: Iron and monocyte-endothelial cell interactions. , 2009, Atherosclerosis.
[28] E. Morgan,et al. Iron trafficking inside the brain , 2007, Journal of neurochemistry.
[29] Rudi Balling,et al. The hallmarks of Parkinson's disease , 2013, The FEBS journal.
[30] H. Schumacher,et al. The Arthropathy of Hemochromatosis , 1988, Annals of the New York Academy of Sciences.
[31] E. Vichinsky,et al. Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. , 2013, American journal of physical medicine & rehabilitation.
[32] P. Carvey,et al. 6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability , 2005, The European journal of neuroscience.
[33] Jerry Kaplan,et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.
[34] H. Schumacher. HEMOCHROMATOSIS AND ARTHRITIS. , 1964, Arthritis and rheumatism.
[35] M. Schwartz,et al. Systemic inflammatory cells fight off neurodegenerative disease , 2010, Nature Reviews Neurology.
[36] J. del Valle,et al. Blood-brain barrier disruption in the striatum of rats treated with 3-nitropropionic acid. , 2009, Neurotoxicology.
[37] U. Bonuccelli,et al. New pharmacologic horizons in the treatment of Parkinson disease , 2006, Neurology.
[38] Elizabeth C. Theil. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. , 1987, Annual review of biochemistry.
[39] Victoria Tapia,et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells , 2013, Journal of neurochemistry.
[40] D. Ogilvie-Harris,et al. Synovial iron deposition in osteoarthritis and rheumatoid arthritis. , 1980, The Journal of rheumatology.
[41] C. Humpel,et al. Primary rat monocytes migrate through a BCEC-monolayer and express microglia-markers at the basolateral side , 2007, Brain Research Bulletin.
[42] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[43] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[44] Khadija Iqbal,et al. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia , 2004, Acta Neuropathologica.
[45] E. Haller,et al. Evidence of Compromised Blood-Spinal Cord Barrier in Early and Late Symptomatic SOD1 Mice Modeling ALS , 2007, PloS one.
[46] E. Morgan,et al. Transferrin and Transferrin Receptor Function in Brain Barrier Systems , 2000, Cellular and Molecular Neurobiology.
[47] T. Moos,et al. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease , 1999, Neuroscience.
[48] A. Ludolph,et al. Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.
[49] G. Hansson. Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. , 2009, Atherosclerosis.
[50] M. Shingu,et al. Iron-binding proteins and free iron in synovial fluids of rheumatoid arthritis patients , 1989, Clinical Rheumatology.
[51] Miikka Vikkula,et al. Cerebrovascular disorders: molecular insights and therapeutic opportunities , 2011, Nature Neuroscience.
[52] W. Hagen,et al. The catalytic center of ferritin regulates iron storage via Fe(II)-Fe(III) displacement. , 2012, Nature chemical biology.
[53] C. Quintana,et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. , 2006, Journal of structural biology.
[54] J. Lichota,et al. Heterogenous distribution of ferroportin-containing neurons in mouse brain , 2011, BioMetals.
[55] P. Anand,et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord , 2006, BMC neurology.
[56] R. Brooks,et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.
[57] G. Arendash,et al. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex , 1995, Neuroscience.
[58] Tzong-Shyuan Lee,et al. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. , 1999, Circulation.
[59] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[60] T. J. Cunningham,et al. Differential immunochemical markers reveal the normal distribution of brain macrophages and microglia in the developing rat brain , 1991, The Journal of comparative neurology.
[61] N. Suttle. Copper imbalances in ruminants and humans: unexpected common ground. , 2012, Advances in nutrition.
[62] H. Rowley,et al. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. , 2006, AJNR. American journal of neuroradiology.
[63] Dale E. Bredesen,et al. Cell death in the nervous system , 2006, Nature.
[64] M. Muckenthaler,et al. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.
[65] M. Sawada,et al. Role of cytokines in inflammatory process in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[66] Wei-jian Zhang,et al. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice , 2010, Experimental biology and medicine.
[67] D. Dexter,et al. Chelating agents for neurodegenerative diseases. , 2012, Current medicinal chemistry.
[68] P. Riederer,et al. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.
[69] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[70] Marek Luczkowski,et al. Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases) , 2012 .
[71] Brian F. Corbett,et al. Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.
[72] U. Dirnagl,et al. Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[73] Ramandeep Singh,et al. Current therapeutic strategy in Alzheimer's disease. , 2012, European review for medical and pharmacological sciences.
[74] Dean Y. Li,et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. , 2010, The Journal of clinical investigation.
[75] R. Ransohoff,et al. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration , 2011, Nature Neuroscience.
[76] S. Gandhi,et al. Mechanism of Oxidative Stress in Neurodegeneration , 2012, Oxidative medicine and cellular longevity.
[77] S. Gordon,et al. Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.
[78] P. Mecocci,et al. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[79] F. Codazzi,et al. Iron uptake in quiescent and inflammation-activated astrocytes: A potentially neuroprotective control of iron burden , 2013, Biochimica et biophysica acta.
[80] Alessandra Solari,et al. Iron‐related MRI images in patients with pantothenate kinase–associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial , 2011, Movement disorders : official journal of the Movement Disorder Society.
[81] P. Sanberg,et al. Neurovascular aspects of amyotrophic lateral sclerosis. , 2012, International review of neurobiology.
[82] Kaan E. Biron,et al. Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization , 2013, Scientific Reports.
[83] A. Mahadevan,et al. Elevated Oxidative Stress and Decreased Antioxidant Function in the Human Hippocampus and Frontal Cortex with Increasing Age: Implications for Neurodegeneration in Alzheimer’s Disease , 2012, Neurochemical Research.
[84] Jeff H. Duyn,et al. Iron Accumulation in Deep Cortical Layers Accounts for MRI Signal Abnormalities in ALS: Correlating 7 Tesla MRI and Pathology , 2012, PloS one.
[85] M. D. Mossalayi,et al. Nitric oxide production by human monocytes: evidence for a role of CD23. , 1995, Immunology today.
[86] D. Cleveland,et al. ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.
[87] K. Pantopoulos,et al. Iron metabolism and toxicity. , 2005, Toxicology and applied pharmacology.
[88] C. Chen. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. , 2011, Chang Gung medical journal.
[89] C. Morris,et al. Relationship between iron deposits and tissue damage in the synovium: an ultrastructural study. , 1986, Annals of the rheumatic diseases.
[90] A. Gregory,et al. Genetics of Neurodegeneration with Brain Iron Accumulation , 2011, Current neurology and neuroscience reports.
[91] J. Cano,et al. Blood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons , 2007, Journal of neurochemistry.
[92] Kaan E. Biron,et al. Amyloid Triggers Extensive Cerebral Angiogenesis Causing Blood Brain Barrier Permeability and Hypervascularity in Alzheimer's Disease , 2011, PloS one.
[93] S. Mandel,et al. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice , 2007, Journal of Neural Transmission.
[94] F. Visseren,et al. Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[95] P. Mcgeer,et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. , 2005, Current Alzheimer research.
[96] J. Connor,et al. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain , 1993, The Journal of comparative neurology.
[97] M. Beal,et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.
[98] M. Linder. The relationship of copper to DNA damage and damage prevention in humans. , 2012, Mutation research.
[99] B. Gwag,et al. Blood-derived iron mediates free radical production and neuronal death in the hippocampal CA1 area following transient forebrain ischemia in rat , 2011, Acta Neuropathologica.
[100] Andrew G. Webb,et al. Elevated brain iron is independent from atrophy in Huntington's Disease , 2012, NeuroImage.
[101] David J. Begley,et al. Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.
[102] Ogilvie-Harris Dj,et al. Synovial iron deposition in osteoarthritis and rheumatoid arthritis. , 1980 .
[103] H. Nazer,et al. Wilson's Disease. , 1991, Annals of Saudi medicine.
[104] D. Reif,et al. Nitric oxide mediates iron release from ferritin. , 1990, Archives of biochemistry and biophysics.
[105] Z. Sheng,et al. Expression of the iron transporter ferroportin in synaptic vesicles and the blood–brain barrier , 2004, Brain Research.
[106] Guy C. Brown,et al. Inflammatory Neurodegeneration and Mechanisms of Microglial Killing of Neurons , 2010, Molecular Neurobiology.
[107] C. Moussa,et al. Inflammation in the early stages of neurodegenerative pathology , 2011, Journal of Neuroimmunology.
[108] P. Levitt,et al. Brain macrophages and microglia respond differently to lesions of the developing and adult visual system , 1991, The Journal of comparative neurology.
[109] D. D. Di Monte,et al. Redox cycling of the herbicide paraquat in microglial cultures. , 2005, Brain research. Molecular brain research.
[110] L. Thal,et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. , 2000, Neurology.
[111] R. Rodnitzky. Upcoming treatments in Parkinson's disease, including gene therapy. , 2012, Parkinsonism & Related Disorders.
[112] Gary Lynch,et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease , 2007, Glia.
[113] J. Cano,et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.
[114] M. Parihar,et al. Reduction of lipid peroxidation in different brain regions by a combination of α-tocopherol and ascorbic acid , 2005, Journal of Neural Transmission.
[115] P. Dallman,et al. Brain iron in the rat: extremely slow turnover in normal rats may explain long-lasting effects of early iron deficiency. , 1977, The Journal of nutrition.
[116] M. Tansey,et al. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.
[117] R. Ordidge,et al. Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.
[118] P Z Marmarelis,et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.
[119] B. Halliwell,et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. , 2005, Free radical biology & medicine.
[120] R. Hider,et al. The potential application of iron chelators for the treatment of neurodegenerative diseases. , 2011, Metallomics : integrated biometal science.
[121] R. Ransohoff,et al. Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.
[122] J. Cummings,et al. Huntington's disease. , 1997, The Psychiatric clinics of North America.
[123] G. Bartzokis,et al. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.
[124] I. Tabas,et al. Macrophage Apoptosis in Advanced Atherosclerosis , 2009, Annals of the New York Academy of Sciences.
[125] Roberta J. Ward,et al. Brain iron metabolism and its perturbation in neurological diseases , 2011, Journal of Neural Transmission.
[126] G. Gerhard,et al. Atherosclerosis: a manifestation of chronic iron toxicity? , 2003, Vascular medicine.
[127] B. Gallois,et al. Mutant Ferritin L-chains That Cause Neurodegeneration Act in a Dominant-negative Manner to Reduce Ferritin Iron Incorporation* , 2010, The Journal of Biological Chemistry.
[128] J. Dankert,et al. PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.
[129] V. Uversky,et al. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.
[130] A. Koeppen,et al. Iron in the Hallervorden-Spatz syndrome. , 2001, Pediatric neurology.
[131] M. Youdim,et al. Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.
[132] R. Yokel,et al. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. , 1996, Toxicology.
[133] S. Koppula,et al. Reactive Oxygen Species and Inhibitors of Inflammatory Enzymes, NADPH Oxidase, and iNOS in Experimental Models of Parkinson's Disease , 2012, Mediators of inflammation.
[134] A. Sun,et al. Cytotoxicity of paraquat in microglial cells: Involvement of PKCδ- and ERK1/2-dependent NADPH oxidase , 2007, Brain Research.
[135] L. Della Corte,et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration , 2011, Journal of Neural Transmission.
[136] B. Ghetti,et al. Expression of a Mutant Form of the Ferritin Light Chain Gene Induces Neurodegeneration and Iron Overload in Transgenic Mice , 2008, The Journal of Neuroscience.
[137] Wei Zhang,et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. , 2005, Antioxidants & redox signaling.
[138] E. Hirsch,et al. Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.
[139] S. Hayflick. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.
[140] M. J. Bández,et al. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. , 2012, Neurotoxicology.
[141] A. Sun,et al. Oxidative and Inflammatory Pathways in Parkinson’s Disease , 2008, Neurochemical Research.
[142] R. El-Bachá,et al. Brain rust: Recent discoveries on the role of oxidative stress in neurodegenerative diseases , 2012, Nutritional neuroscience.
[143] E. Ling,et al. Iron and Iron Regulatory Proteins in Amoeboid Microglial Cells Are Linked to Oligodendrocyte Death in Hypoxic Neonatal Rat Periventricular White Matter through Production of Proinflammatory Cytokines and Reactive Oxygen/Nitrogen Species , 2011, The Journal of Neuroscience.
[144] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[145] D. Ruano,et al. Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic , 2008, The Journal of Neuroscience.
[146] K. Jellinger,et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.
[147] J. Kehrer. The Haber-Weiss reaction and mechanisms of toxicity. , 2000, Toxicology.
[148] M. Davies,et al. Direct Detection and Quantification of Transition Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of Elevated Levels of Iron and Copper , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[149] G. Reynolds,et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.
[150] C. Cunningham. Microglia and neurodegeneration: The role of systemic inflammation , 2013, Glia.
[151] J. Haorah,et al. Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions , 2006, Journal of Neuroimmune Pharmacology.
[152] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[153] C. Morris,et al. Iron in joint inflammation. , 1993, Annals of the rheumatic diseases.
[154] E. Fibach,et al. Flow cytometry measurement of the labile iron pool in human hematopoietic cells , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[155] D. Girelli,et al. Differential regulation of iron homeostasis during human macrophage polarized activation , 2010, European journal of immunology.
[156] P. Mander,et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.
[157] C. Palmer,et al. Cellular distribution of ferritin subunits in postnatal rat brain , 1998, The Journal of comparative neurology.
[158] R J Simpson,et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. , 2000, Molecular cell.
[159] T. Rouault,et al. Iron metabolism in the CNS: implications for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.
[160] H. Lassmann. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease , 2011, Journal of Neural Transmission.
[161] R. Bennett,et al. Synovial iron deposition in rheumatoid arthritis. , 1973, Arthritis and rheumatism.
[162] J. Connor,et al. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat , 2001, Journal of neuroscience research.
[163] M. Locati,et al. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. , 2012, Autoimmunity reviews.
[164] S. Hirai,et al. Activated microglia cause superoxide-mediated release of iron from ferritin , 1995, Neuroscience Letters.
[165] A. Luster,et al. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. , 2008, Trends in pharmacological sciences.
[166] E. Hirsch. Altered regulation of iron transport and storage in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[167] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[168] N. Van Rooijen,et al. Ulcerative colitis exacerbates lipopolysaccharide‐induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease , 2010, Journal of neurochemistry.
[169] E. Morgan,et al. Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. , 2000, Cellular and molecular biology.
[170] D. Sparks,et al. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity , 2008, Glia.
[171] I. Kohane,et al. Gene regulation and DNA damage in the ageing human brain , 2004, Nature.
[172] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.